Related Experiment Videos
[Pharmacokinetics and clinical efficacy of flomoxef in neonates]
Abstract:
Clinical pharmacology and efficacy of flomoxef (FMOX) in neonates were investigated. And the following results were obtained. 1. Mean serum concentrations of FMOX at 30 minutes after administration were 24.3 micrograms/ml, 47.6 micrograms/ml, and 85.8 micrograms/ml at doses of 10 mg/kg, 20 mg/kg, and 40 mg/kg administered, respectively. 2. Mean serum half-lives of FMOX were 3.4 hours in 0-3 day-old neonates, and 2.6 hours in 4 day-old or older subjects. 3. A dose response was evident among different dose groups given 10 mg/kg, 20 mg/kg, and 40 mg/kg. 4. Urinary recovery rates of FMOX in the first 6 hours after administration ranged between 12.8 and 51.1%. 5. FMOX was effective in 7 out of 8 cases in which causative pathogens were identified. 6. Diarrhea was observed in 1 case as a side effect of the drug, but the symptom was relieved soon after the completion of the treatment. There was no case in which any abnormal laboratory results were observed. 7. FMOX has a broad spectrum of activities against Gram-positive and Gram-negative aerobes and anaerobes. It is stable against most of beta-lactamases. It was demonstrated to be highly effective in our study, and yet without any serious side effects. FMOX is therefore considered to be one of the useful agents of the first choice for the treatment of bacterial infections such as sepsis and urinary tract infections in neonates and infants.
Insights
Flomoxef (FMOX) demonstrates dose-dependent serum concentrations and efficacy in neonates. This antibiotic is effective against bacterial infections with minimal side effects, making it a valuable treatment option.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Infectious Diseases
Background:
- Investigating the clinical pharmacology and efficacy of flomoxef (FMOX) in neonates is crucial for establishing safe and effective treatment protocols.
- Understanding drug pharmacokinetics, including serum concentrations and half-lives, is essential for optimizing dosing in this vulnerable population.
Observation:
- Flomoxef (FMOX) exhibited dose-dependent serum concentrations, with higher doses yielding greater levels.
- Mean serum half-lives varied based on neonatal age, suggesting age-specific pharmacokinetic considerations.
- Urinary recovery rates indicated variable excretion patterns of FMOX.
- The drug showed significant effectiveness in treating identified bacterial infections in neonates.
Findings:
- A clear dose-response relationship was observed for flomoxef (FMOX) across the studied dosage range (10-40 mg/kg).
- Flomoxef (FMOX) demonstrated broad-spectrum activity against Gram-positive and Gram-negative bacteria, including anaerobes, and stability against most beta-lactamases.
- The antibiotic was effective in 7 of 8 cases with identified pathogens, with only mild, transient diarrhea reported as a side effect.
Implications:
- Flomoxef (FMOX) is a promising first-choice agent for treating neonatal bacterial infections like sepsis and urinary tract infections.
- Its favorable efficacy and safety profile in neonates warrant further clinical consideration and application.
- The study supports the use of flomoxef (FMOX) as a reliable therapeutic option in neonatal care settings.